| AstraZeneca |
54 |
24 |
13 |
EGFR exon 19 deletion / L858R 13BRCA1/2 mutation 10Claudin 18.2 expression 7HER2-low / ultralow (IHC 1+ or 2+/ISH-) 5+9 |
| Roche |
25 |
10 |
7 |
PIK3CA activating mutation 8KRAS G12C 6ALK fusion 6ROS1 fusion 4+3 |
| Eli Lilly |
22 |
9 |
7 |
RET fusion or mutation 7KRAS G12C 5IDH1/2 mutation 3PIK3CA activating mutation 2+3 |
| Jiangsu Hengrui |
22 |
9 |
6 |
KRAS G12D 4Claudin 18.2 expression 4KRAS G12C 3HER2-low / ultralow (IHC 1+ or 2+/ISH-) 2+2 |
| Johnson & Johnson |
20 |
8 |
4 |
EGFR exon 19 deletion / L858R 7EGFR exon 20 insertion 4NPM1 mutation 3MET exon 14 skipping 1 |
| MSD (Merck & Co.) |
20 |
9 |
3 |
KRAS G12C 10MSI-H / dMMR 7BRCA1/2 mutation 1 |
| Bristol Myers Squibb |
18 |
8 |
7 |
KRAS G12C 8EGFR exon 19 deletion / L858R 3ROS1 fusion 3ALK fusion 2+3 |
| Novartis |
18 |
6 |
9 |
PIK3CA activating mutation 5KRAS G12C 3ALK fusion 2MSI-H / dMMR 2+5 |
| Astellas |
16 |
7 |
5 |
Claudin 18.2 expression 10KRAS G12D 3KRAS G12C 1FLT3 mutation (ITD/TKD) 1+1 |
| Daiichi Sankyo |
16 |
3 |
7 |
HER2-low / ultralow (IHC 1+ or 2+/ISH-) 7EGFR exon 19 deletion / L858R 4HER2 (ERBB2) activating mutation 2FLT3 mutation (ITD/TKD) 2+3 |
| Pfizer |
15 |
5 |
8 |
BRAF V600E 4ALK fusion 3HER2-low / ultralow (IHC 1+ or 2+/ISH-) 2PIK3CA activating mutation 1+4 |
| Hansoh Pharma |
14 |
4 |
5 |
EGFR exon 19 deletion / L858R 5KRAS G12C 4EGFR exon 20 insertion 1KRAS G12D 1+1 |
| Baili-Bio / SystImmune |
13 |
7 |
6 |
HER2-low / ultralow (IHC 1+ or 2+/ISH-) 5EGFR exon 19 deletion / L858R 1EGFR exon 20 insertion 1KRAS G12C 1+2 |
| Avistone Biotechnology |
12 |
2 |
5 |
EGFR exon 20 insertion 2ROS1 fusion 2EGFR exon 19 deletion / L858R 1MET exon 14 skipping 1+1 |
| Revolution Medicines |
12 |
5 |
2 |
KRAS G12D 6KRAS G12C 3 |
| GSK |
11 |
5 |
2 |
MSI-H / dMMR 9BRCA1/2 mutation 2 |
| Allist Pharmaceuticals |
10 |
4 |
3 |
KRAS G12C 6EGFR exon 19 deletion / L858R 3EGFR exon 20 insertion 1 |
| Bayer |
10 |
1 |
5 |
HER2 (ERBB2) activating mutation 3MSI-H / dMMR 3KRAS G12C 1KRAS G12D 1+1 |
| Innovent Biologics |
9 |
3 |
4 |
Claudin 18.2 expression 5EGFR exon 19 deletion / L858R 2KRAS G12C 1MSI-H / dMMR 1 |
| Abbisko Therapeutics |
8 |
0 |
6 |
FGFR3 alteration (mutation or fusion) 2EGFR exon 19 deletion / L858R 1EGFR exon 20 insertion 1KRAS G12C 1+2 |
| AbbVie |
8 |
2 |
5 |
EGFR exon 19 deletion / L858R 3BRCA1/2 mutation 2BRAF V600E 1IDH1/2 mutation 1+1 |
| CSPC |
8 |
4 |
7 |
ALK fusion 2EGFR exon 19 deletion / L858R 1HER2 (ERBB2) activating mutation 1FLT3 mutation (ITD/TKD) 1+3 |
| Dizal Pharmaceuticals |
8 |
1 |
3 |
EGFR exon 19 deletion / L858R 3EGFR exon 20 insertion 3HER2 (ERBB2) activating mutation 1 |
| Genfleet Therapeutics |
8 |
1 |
1 |
KRAS G12D 5 |
| Kelun-Biotech |
8 |
2 |
2 |
Claudin 18.2 expression 2RET fusion or mutation 1 |
| Amgen |
7 |
2 |
2 |
KRAS G12C 4MSI-H / dMMR 1 |
| Betta Pharmaceuticals |
7 |
1 |
3 |
EGFR exon 19 deletion / L858R 5EGFR exon 20 insertion 1MET exon 14 skipping 1 |
| Boehringer Ingelheim |
7 |
2 |
2 |
HER2 (ERBB2) activating mutation 5KRAS G12C 1 |
| Chia Tai Tianqing (Sino Biopharm) |
7 |
4 |
3 |
IDH1/2 mutation 3HER2-low / ultralow (IHC 1+ or 2+/ISH-) 2KRAS G12C 1 |
| Nuvation Bio |
7 |
4 |
2 |
ROS1 fusion 4IDH1/2 mutation 3 |
| Qilu Pharmaceutical |
7 |
1 |
3 |
Claudin 18.2 expression 3KRAS G12D 2MSI-H / dMMR 2 |
| RemeGen |
7 |
1 |
4 |
HER2-low / ultralow (IHC 1+ or 2+/ISH-) 4EGFR exon 19 deletion / L858R 1HER2 (ERBB2) activating mutation 1Claudin 18.2 expression 1 |
| Taiho Pharmaceutical |
6 |
2 |
4 |
EGFR exon 20 insertion 3EGFR exon 19 deletion / L858R 1RET fusion or mutation 1FGFR2 fusion or rearrangement 1 |
| HUTCHMED |
5 |
3 |
4 |
IDH1/2 mutation 2EGFR exon 19 deletion / L858R 1NPM1 mutation 1FGFR2 fusion or rearrangement 1 |
| Incyte |
5 |
2 |
3 |
KRAS G12D 3ALK fusion 1FGFR2 fusion or rearrangement 1 |
| Jiangsu Aosaikang Pharmaceutical |
5 |
2 |
2 |
EGFR exon 19 deletion / L858R 2Claudin 18.2 expression 1 |
| Kura Oncology |
5 |
1 |
2 |
NPM1 mutation 4FLT3 mutation (ITD/TKD) 2 |
| Pierre Fabre Medicament |
5 |
1 |
4 |
BRAF V600E 2EGFR exon 19 deletion / L858R 1HER2 (ERBB2) activating mutation 1MET exon 14 skipping 1 |
| Verastem |
5 |
0 |
2 |
KRAS G12D 4KRAS G12C 1 |
| Beijing Biotech |
4 |
0 |
1 |
Claudin 18.2 expression 4 |
| BioNTech |
4 |
0 |
5 |
EGFR exon 19 deletion / L858R 3ALK fusion 2ROS1 fusion 1RET fusion or mutation 1+1 |
| Fosun Pharma |
4 |
2 |
2 |
BRAF V600E 1ALK fusion 1 |
| Guangzhou JOYO Pharma |
4 |
2 |
1 |
ROS1 fusion 3 |
| Haisco Pharmaceutical Group |
4 |
0 |
0 |
|
| Henlius |
4 |
1 |
2 |
ROS1 fusion 1HER2-low / ultralow (IHC 1+ or 2+/ISH-) 1 |
| InxMed |
4 |
1 |
2 |
KRAS G12C 2KRAS G12D 1 |
| Kumquat Biosciences |
4 |
0 |
3 |
KRAS G12C 2EGFR exon 20 insertion 1KRAS G12D 1 |
| MediLink Therapeutics |
4 |
1 |
2 |
EGFR exon 19 deletion / L858R 2HER2-low / ultralow (IHC 1+ or 2+/ISH-) 1 |
| Nuvalent |
4 |
1 |
3 |
ALK fusion 2HER2 (ERBB2) activating mutation 1ROS1 fusion 1 |
| Shanghai JMT-Bio |
4 |
3 |
2 |
EGFR exon 20 insertion 1MSI-H / dMMR 1 |
| Teligene |
4 |
0 |
2 |
NTRK1/2/3 fusion 1MSI-H / dMMR 1 |
| TYK Medicines |
4 |
1 |
0 |
|
| Antengene Biologics |
3 |
1 |
1 |
Claudin 18.2 expression 3 |
| Ascentage Pharma Group |
3 |
0 |
2 |
ALK fusion 2ROS1 fusion 2 |
| Beijing Pearl Biotechnology |
3 |
2 |
2 |
IDH1/2 mutation 1MET exon 14 skipping 1 |
| BeOne Medicines (BeiGene) |
3 |
0 |
1 |
MSI-H / dMMR 1 |
| BridgeBio Oncology Therapeutics |
3 |
0 |
2 |
KRAS G12C 2PIK3CA activating mutation 1 |
| CARsgen Therapeutics |
3 |
0 |
1 |
Claudin 18.2 expression 3 |
| Cogent Biosciences |
3 |
0 |
3 |
PIK3CA activating mutation 1HER2 (ERBB2) activating mutation 1NRG1 fusion 1 |
| D3 Bio |
3 |
0 |
3 |
KRAS G12C 2EGFR exon 20 insertion 1KRAS G12D 1 |
| Exelixis |
3 |
1 |
3 |
MSI-H / dMMR 2BRAF V600E 1BRCA1/2 mutation 1 |
| Genmab |
3 |
2 |
1 |
BRCA1/2 mutation 3 |
| Gilead Sciences |
3 |
1 |
2 |
BRCA1/2 mutation 2HER2-low / ultralow (IHC 1+ or 2+/ISH-) 1 |
| InventisBio |
3 |
0 |
2 |
KRAS G12C 2MSI-H / dMMR 1 |
| Jemincare |
3 |
1 |
2 |
KRAS G12C 2MSI-H / dMMR 1 |
| Jiangsu Alphamab Biopharmaceuticals |
3 |
1 |
3 |
KRAS G12C 1HER2 (ERBB2) activating mutation 1HER2-low / ultralow (IHC 1+ or 2+/ISH-) 1 |
| Nuvectis Pharma |
3 |
0 |
2 |
IDH1/2 mutation 1ALK fusion 1 |
| Shanghai Institute Of Biological Products |
3 |
0 |
2 |
HER2-low / ultralow (IHC 1+ or 2+/ISH-) 1Claudin 18.2 expression 1 |
| Shenzhen TargetRx |
3 |
1 |
2 |
ALK fusion 3ROS1 fusion 1 |
| SmartNuclide Biopharma |
3 |
0 |
1 |
Claudin 18.2 expression 3 |
| Stemline Therapeutics |
3 |
0 |
2 |
PIK3CA activating mutation 2ESR1 mutation 1 |
| Syndax Pharmaceuticals |
3 |
1 |
1 |
NPM1 mutation 3 |
| Tyra Biosciences |
3 |
0 |
2 |
FGFR3 alteration (mutation or fusion) 2FGFR2 fusion or rearrangement 1 |
| 3D Medicines |
2 |
0 |
2 |
FGFR2 fusion or rearrangement 1MSI-H / dMMR 1 |
| 3H (Suzhou) Pharmaceuticals |
2 |
0 |
1 |
FGFR2 fusion or rearrangement 2 |
| Adlai Nortye Biopharma |
2 |
0 |
0 |
|
| Akeso |
2 |
2 |
1 |
MSI-H / dMMR 1 |
| ArriVent BioPharma |
2 |
1 |
2 |
EGFR exon 20 insertion 2HER2 (ERBB2) activating mutation 1 |
| AskGene Pharma |
2 |
1 |
1 |
Claudin 18.2 expression 2 |
| BeBetter Med |
2 |
0 |
2 |
EGFR exon 20 insertion 2HER2 (ERBB2) activating mutation 1 |
| Beijing InnoCare Pharma Tech |
2 |
0 |
2 |
NTRK1/2/3 fusion 1FGFR2 fusion or rearrangement 1 |
| Black Diamond Therapeutics |
2 |
0 |
0 |
|
| Chipscreen Biosciences |
2 |
0 |
1 |
MSI-H / dMMR 2 |
| Compass Therapeutics |
2 |
0 |
2 |
HER2-low / ultralow (IHC 1+ or 2+/ISH-) 1MSI-H / dMMR 1 |
| Convalife |
2 |
0 |
1 |
MSI-H / dMMR 1 |
| Cullinan Therapeutics |
2 |
0 |
1 |
EGFR exon 20 insertion 1 |
| DualityBio |
2 |
1 |
1 |
HER2-low / ultralow (IHC 1+ or 2+/ISH-) 2 |
| FutureGen Biopharmaceutical |
2 |
1 |
1 |
Claudin 18.2 expression 2 |
| Henan Genuine Biotech |
2 |
0 |
0 |
|
| HiFiBiO Therapeutics |
2 |
0 |
1 |
BRAF V600E 2 |
| Hummingbird Bioscience |
2 |
0 |
1 |
NRG1 fusion 1 |
| HUYABIO International |
2 |
0 |
1 |
KRAS G12C 1 |
| I-Mab Biopharma US |
2 |
0 |
1 |
Claudin 18.2 expression 2 |
| Jiangxi Kvvit Pharmaceutical |
2 |
2 |
1 |
KRAS G12D 2 |
| LaNova Medicines Zhejiang |
2 |
1 |
1 |
Claudin 18.2 expression 2 |
| Merck KGaA |
2 |
0 |
1 |
MET exon 14 skipping 1 |
| Multitude Therapeutics |
2 |
1 |
0 |
|
| ORIC Pharmaceuticals |
2 |
0 |
2 |
EGFR exon 20 insertion 2HER2 (ERBB2) activating mutation 1 |
| PAQ Therapeutics |
2 |
0 |
1 |
KRAS G12D 1 |
| Quanta Therapeutics |
2 |
0 |
1 |
KRAS G12D 2 |
| Radiopharm Theranostics |
2 |
0 |
2 |
HER2-low / ultralow (IHC 1+ or 2+/ISH-) 1MSI-H / dMMR 1 |
| Ranok Therapeutics |
2 |
0 |
1 |
KRAS G12D 2 |
| Relay Therapeutics |
2 |
1 |
1 |
PIK3CA activating mutation 2 |
| Replimune |
2 |
1 |
1 |
MSI-H / dMMR 1 |
| Rigel Pharmaceuticals |
2 |
2 |
2 |
IDH1/2 mutation 1RET fusion or mutation 1 |
| Sapience Therapeutics |
2 |
0 |
1 |
BRCA1/2 mutation 1 |
| Servier |
2 |
1 |
2 |
IDH1/2 mutation 1NPM1 mutation 1 |
| Servier Affaires Médicales |
2 |
2 |
1 |
IDH1/2 mutation 2 |
| Servier Bio-Innovation |
2 |
1 |
2 |
IDH1/2 mutation 1MSI-H / dMMR 1 |
| Sichuan Huiyu Pharmaceutical |
2 |
0 |
1 |
MSI-H / dMMR 1 |
| Sunshine Lake Pharma |
2 |
1 |
1 |
FLT3 mutation (ITD/TKD) 2 |
| Takeda |
2 |
0 |
2 |
EGFR exon 20 insertion 2HER2 (ERBB2) activating mutation 1 |
| Tango Therapeutics |
2 |
0 |
0 |
|
| Transcenta Therapeutics |
2 |
1 |
1 |
Claudin 18.2 expression 2 |
| TransThera Sciences |
2 |
2 |
1 |
FGFR2 fusion or rearrangement 1 |
| Treeline Biosciences |
2 |
0 |
1 |
ALK fusion 1 |
| Wayshine Biopharm |
2 |
0 |
0 |
|
| Xcovery Holdings |
2 |
1 |
1 |
ALK fusion 1 |
| Xuanzhu Biopharmaceutical |
2 |
0 |
3 |
HER2 (ERBB2) activating mutation 1ROS1 fusion 1NTRK1/2/3 fusion 1 |
| Zhejiang Anglikang Pharmaceutical |
2 |
0 |
2 |
HER2-low / ultralow (IHC 1+ or 2+/ISH-) 1MSI-H / dMMR 1 |
| 23andMe |
1 |
0 |
1 |
MSI-H / dMMR 1 |
| 7 Hills Pharma |
1 |
0 |
1 |
MSI-H / dMMR 1 |
| Abion |
1 |
0 |
1 |
MET exon 14 skipping 1 |
| AffyImmune Therapeutics |
1 |
0 |
0 |
|
| AGO Research |
1 |
0 |
1 |
BRCA1/2 mutation 1 |
| Alpha Biopharma |
1 |
0 |
0 |
|
| Alterome Therapeutics |
1 |
0 |
0 |
|
| Alyssum Therapeutics |
1 |
0 |
1 |
BRCA1/2 mutation 1 |
| Aminex Therapeutics |
1 |
0 |
1 |
PIK3CA activating mutation 1 |
| Anbogen Therapeutics |
1 |
0 |
1 |
HER2 (ERBB2) activating mutation 1 |
| Anova Innovation |
1 |
0 |
1 |
Claudin 18.2 expression 1 |
| Apollomics |
1 |
0 |
1 |
MET exon 14 skipping 1 |
| Applied Pharmaceutical Science |
1 |
0 |
1 |
RET fusion or mutation 1 |
| Artios Pharma |
1 |
0 |
1 |
BRCA1/2 mutation 1 |
| Arvinas |
1 |
0 |
1 |
KRAS G12D 1 |
| Asieris Pharmaceuticals |
1 |
0 |
0 |
|
| Aston Sci |
1 |
0 |
1 |
HER2-low / ultralow (IHC 1+ or 2+/ISH-) 1 |
| Aulos Bioscience |
1 |
0 |
1 |
ALK fusion 1 |
| Auricula Biosciences |
1 |
0 |
0 |
|
| Biohaven Therapeutics |
1 |
0 |
1 |
FGFR3 alteration (mutation or fusion) 1 |
| BlossomHill Therapeutics |
1 |
0 |
1 |
HER2 (ERBB2) activating mutation 1 |
| Blueprint Medicines |
1 |
0 |
1 |
KRAS G12C 1 |
| BOE Technology Group |
1 |
0 |
0 |
|
| Boryung Pharmaceutical |
1 |
0 |
1 |
BRCA1/2 mutation 1 |
| Bridge Biotherapeutics |
1 |
0 |
1 |
EGFR exon 19 deletion / L858R 1 |
| Buzzard Pharmaceuticals |
1 |
0 |
0 |
|
| Calico Life Sciences |
1 |
0 |
1 |
MSI-H / dMMR 1 |
| Cardiff Oncology |
1 |
0 |
0 |
|
| CarThera |
1 |
1 |
0 |
|
| Celest Therapeutics |
1 |
0 |
1 |
Claudin 18.2 expression 1 |
| Cerenome |
1 |
0 |
0 |
|
| Changchun GeneScience Pharmaceutical |
1 |
0 |
1 |
PIK3CA activating mutation 1 |
| Charm Therapeutics |
1 |
0 |
1 |
NPM1 mutation 1 |
| Checkpoint Therapeutics |
1 |
0 |
1 |
MSI-H / dMMR 1 |
| Chengdu JOYO pharma |
1 |
1 |
1 |
PIK3CA activating mutation 1 |
| Chengdu Ucello Biotechnology |
1 |
0 |
1 |
Claudin 18.2 expression 1 |
| Chong Kun Dang Pharmaceutical |
1 |
0 |
1 |
BRCA1/2 mutation 1 |
| Chongqing Precision Biotech |
1 |
0 |
1 |
ALK fusion 1 |
| Conjupro Biotherapeutics |
1 |
0 |
0 |
|
| Corregene Biotechnology |
1 |
0 |
0 |
|
| Crimson Biopharm |
1 |
0 |
0 |
|
| Criterium |
1 |
0 |
1 |
PIK3CA activating mutation 1 |
| CrystalGenomics |
1 |
0 |
1 |
ALK fusion 1 |
| D. E. Shaw Research |
1 |
0 |
1 |
MSI-H / dMMR 1 |
| Daewoong Pharmaceutical |
1 |
0 |
1 |
BRCA1/2 mutation 1 |
| Danatlas Pharmaceuticals |
1 |
0 |
1 |
BRCA1/2 mutation 1 |
| Day One Biopharmaceuticals |
1 |
0 |
0 |
|
| Debiopharm International |
1 |
0 |
1 |
IDH1/2 mutation 1 |
| Degron Therapeutics |
1 |
0 |
0 |
|
| DeuterOncology |
1 |
0 |
1 |
MET exon 14 skipping 1 |
| DIGMBIO |
1 |
0 |
1 |
BRCA1/2 mutation 1 |
| Dizal (Jiangsu) Pharmaceutical |
1 |
1 |
1 |
EGFR exon 20 insertion 1 |
| Dong-A ST |
1 |
0 |
1 |
Claudin 18.2 expression 1 |
| Eikon Therapeutics |
1 |
0 |
1 |
MSI-H / dMMR 1 |
| Eisai |
1 |
0 |
1 |
MSI-H / dMMR 1 |
| Elevar Therapeutics |
1 |
0 |
1 |
FGFR2 fusion or rearrangement 1 |
| Elicio Therapeutics |
1 |
0 |
1 |
KRAS G12C 1 |
| Ellipses Pharma |
1 |
0 |
1 |
RET fusion or mutation 1 |
| Enliven Therapeutics |
1 |
0 |
1 |
HER2 (ERBB2) activating mutation 1 |
| Ensem Therapeutics |
1 |
0 |
1 |
PIK3CA activating mutation 1 |
| EpiBiologics |
1 |
0 |
0 |
|
| Ever Supreme Bio Technology |
1 |
0 |
1 |
BRCA1/2 mutation 1 |
| FluoGuide A/S |
1 |
0 |
1 |
IDH1/2 mutation 1 |
| Fore Biotherapeutics |
1 |
0 |
1 |
BRAF V600E 1 |
| Foresight Therapeutics |
1 |
0 |
1 |
MSI-H / dMMR 1 |
| Forward Pharmaceuticals |
1 |
0 |
1 |
ESR1 mutation 1 |
| FoRx Therapeutics |
1 |
0 |
1 |
BRCA1/2 mutation 1 |
| Frontier Medicines |
1 |
0 |
1 |
KRAS G12C 1 |
| Fujifilm Pharmaceuticals U |
1 |
0 |
1 |
IDH1/2 mutation 1 |
| GeneCraft |
1 |
0 |
0 |
|
| General Oncology |
1 |
0 |
1 |
BRCA1/2 mutation 1 |
| GeneSail Biotech |
1 |
0 |
1 |
BRCA1/2 mutation 1 |
| Genfit |
1 |
0 |
0 |
|
| Genprex |
1 |
0 |
0 |
|
| Genuine Seed Therapeutics |
1 |
0 |
0 |
|
| Georgiamune |
1 |
0 |
0 |
|
| GT Medical Technologies |
1 |
1 |
1 |
IDH1/2 mutation 1 |
| Guangzhou Xiling Biotechnology |
1 |
0 |
1 |
MSI-H / dMMR 1 |
| Haihe Biopharma |
1 |
0 |
1 |
MET exon 14 skipping 1 |
| Hangzhou Sumgen Biotech |
1 |
0 |
1 |
Claudin 18.2 expression 1 |
| Hangzhou SynRx Therapeutics Biomedical Technology |
1 |
0 |
1 |
BRCA1/2 mutation 1 |
| HighField Biopharmaceuticals |
1 |
0 |
1 |
HER2-low / ultralow (IHC 1+ or 2+/ISH-) 1 |
| Hrain Biotechnology |
1 |
0 |
1 |
FLT3 mutation (ITD/TKD) 1 |
| Huabo Biopharm |
1 |
0 |
1 |
ALK fusion 1 |
| Iksuda Therapeutics |
1 |
0 |
1 |
HER2-low / ultralow (IHC 1+ or 2+/ISH-) 1 |
| Immuneering |
1 |
0 |
0 |
|
| Immunitas Therapeutics |
1 |
0 |
2 |
BRCA1/2 mutation 1MSI-H / dMMR 1 |
| ImmunityBio |
1 |
1 |
0 |
|
| Impact Therapeutics |
1 |
1 |
1 |
BRCA1/2 mutation 1 |
| IMV |
1 |
0 |
1 |
MSI-H / dMMR 1 |
| Indaptus Therapeutics |
1 |
0 |
1 |
MSI-H / dMMR 1 |
| Inhibrx Biosciences |
1 |
0 |
1 |
MSI-H / dMMR 1 |
| Institut de Recherches Internationales Servier (I.R.I.S.) |
1 |
0 |
1 |
NPM1 mutation 1 |
| Iovance Biotherapeutics |
1 |
0 |
0 |
|
| Ipsen |
1 |
0 |
0 |
|
| Isofol Medical |
1 |
0 |
0 |
|
| J Ints Bio |
1 |
0 |
0 |
|
| Jacobio Pharmaceuticals |
1 |
0 |
0 |
|
| Jazz Pharmaceuticals |
1 |
0 |
1 |
MSI-H / dMMR 1 |
| JiaRay Group |
1 |
0 |
1 |
MSI-H / dMMR 1 |
| Joint Biosciences |
1 |
0 |
1 |
MSI-H / dMMR 1 |
| Jubilant Therapeutics |
1 |
0 |
1 |
IDH1/2 mutation 1 |
| Kangabio |
1 |
0 |
0 |
|
| KinoTeck Therapeutics |
1 |
0 |
1 |
FGFR2 fusion or rearrangement 1 |
| Kissei Pharmaceutical |
1 |
0 |
1 |
IDH1/2 mutation 1 |
| Klus Pharma |
1 |
0 |
0 |
|
| KymaThera |
1 |
0 |
1 |
PIK3CA activating mutation 1 |
| Kyowa Kirin |
1 |
0 |
1 |
NPM1 mutation 1 |
| Laekna |
1 |
1 |
1 |
PIK3CA activating mutation 1 |
| LaNova Medicines |
1 |
0 |
1 |
MSI-H / dMMR 1 |
| Lantern Pharma |
1 |
0 |
0 |
|
| Leadingtac Pharmaceutical (Shaoxing) |
1 |
0 |
1 |
KRAS G12D 1 |
| Legend Biotech USA |
1 |
0 |
1 |
Claudin 18.2 expression 1 |
| LeonaBio |
1 |
1 |
1 |
ESR1 mutation 1 |
| LigaChem Biosciences |
1 |
0 |
1 |
Claudin 18.2 expression 1 |
| Lomond Therapeutics Holdings |
1 |
0 |
1 |
FLT3 mutation (ITD/TKD) 1 |
| Luye Pharma Group |
1 |
0 |
0 |
|
| MabQuest |
1 |
0 |
1 |
MSI-H / dMMR 1 |
| Marengo Therapeutics |
1 |
0 |
1 |
MSI-H / dMMR 1 |
| Medicine Invention Design |
1 |
1 |
1 |
ALK fusion 1 |
| MEKanistic Therapeutics |
1 |
0 |
0 |
|
| Meryx |
1 |
0 |
1 |
FLT3 mutation (ITD/TKD) 1 |
| Miltenyi Biomedicine |
1 |
0 |
1 |
NPM1 mutation 1 |
| MOMA Therapeutics |
1 |
0 |
1 |
MSI-H / dMMR 1 |
| Nalo Therapeutics |
1 |
0 |
2 |
EGFR exon 19 deletion / L858R 1EGFR exon 20 insertion 1 |
| Nanjing Sanhome Pharmaceutical |
1 |
1 |
1 |
EGFR exon 19 deletion / L858R 1 |
| Natera |
1 |
0 |
1 |
MSI-H / dMMR 1 |
| Neonc Technologies |
1 |
0 |
1 |
IDH1/2 mutation 1 |
| Nested Therapeutics |
1 |
0 |
0 |
|
| Newsoara Biopharma |
1 |
0 |
0 |
|
| NextPoint Therapeutics |
1 |
0 |
0 |
|
| NingBo Junyan Hongshi Biosciences |
1 |
1 |
1 |
Claudin 18.2 expression 1 |
| Nouscom |
1 |
0 |
1 |
MSI-H / dMMR 1 |
| OBI Pharma |
1 |
0 |
1 |
EGFR exon 19 deletion / L858R 1 |
| Oncolytics Biotech |
1 |
0 |
0 |
|
| OnKure |
1 |
0 |
1 |
HER2-low / ultralow (IHC 1+ or 2+/ISH-) 1 |
| Orion Pharma |
1 |
0 |
1 |
KRAS G12C 1 |
| Oryzon Genomics |
1 |
0 |
1 |
FLT3 mutation (ITD/TKD) 1 |
| OSE Immunotherapeutics |
1 |
1 |
1 |
KRAS G12C 1 |
| Parabilis Medicines |
1 |
0 |
1 |
MSI-H / dMMR 1 |
| Partner Therapeutics |
1 |
0 |
1 |
NRG1 fusion 1 |
| PharmaMar |
1 |
0 |
1 |
BRCA1/2 mutation 1 |
| Pharosgen |
1 |
0 |
0 |
|
| Philogen S.p.A. |
1 |
0 |
1 |
IDH1/2 mutation 1 |
| PhotonPharma |
1 |
0 |
1 |
BRCA1/2 mutation 1 |
| Pieris Pharmaceuticals |
1 |
0 |
1 |
HER2-low / ultralow (IHC 1+ or 2+/ISH-) 1 |
| Pikavation Therapeutics |
1 |
0 |
1 |
PIK3CA activating mutation 1 |
| Precision Biologics |
1 |
0 |
2 |
BRAF V600E 1MSI-H / dMMR 1 |
| Ranok Therapuetics |
1 |
0 |
1 |
KRAS G12D 1 |
| Rapa Therapeutics |
1 |
0 |
0 |
|
| RasCal Therapeutics |
1 |
0 |
0 |
|
| Recursion Pharmaceuticals |
1 |
0 |
1 |
PIK3CA activating mutation 1 |
| Regeneron |
1 |
0 |
0 |
|
| Regor Pharmaceuticals |
1 |
0 |
1 |
PIK3CA activating mutation 1 |
| Risen (Suzhou) Pharma Tech |
1 |
1 |
1 |
PIK3CA activating mutation 1 |
| Sanofi |
1 |
0 |
1 |
MSI-H / dMMR 1 |
| Scancell |
1 |
1 |
0 |
|
| ScinnoHub Pharmaceutical |
1 |
0 |
1 |
RET fusion or mutation 1 |
| Sellas Life Sciences Group |
1 |
0 |
0 |
|
| Senhwa Biosciences |
1 |
0 |
1 |
BRCA1/2 mutation 1 |
| Servier (Tianjin) Pharmaceutical |
1 |
0 |
1 |
IDH1/2 mutation 1 |
| Shandong Boan Biotechnology |
1 |
0 |
1 |
MSI-H / dMMR 1 |
| Shandong New Time Pharmaceutical |
1 |
0 |
1 |
Claudin 18.2 expression 1 |
| Shanghai Best-Link Bioscience |
1 |
0 |
0 |
|
| Shanghai Chia Tai Tianqing Pharmaceutical Technology Development |
1 |
1 |
1 |
Claudin 18.2 expression 1 |
| Shanghai Huaota Biopharmaceutical |
1 |
0 |
1 |
HER2-low / ultralow (IHC 1+ or 2+/ISH-) 1 |
| Shanghai Jeyou Pharmaceutical |
1 |
1 |
1 |
KRAS G12C 1 |
| Shanghai Kechow Pharma |
1 |
1 |
1 |
BRAF V600E 1 |
| Shanghai SciBrunch Therapeutics |
1 |
0 |
1 |
BRCA1/2 mutation 1 |
| Shanghai YingLi Pharmaceutical |
1 |
0 |
0 |
|
| Shenyang Sunshine Pharmaceutical |
1 |
0 |
1 |
HER2-low / ultralow (IHC 1+ or 2+/ISH-) 1 |
| Shenzhen Celconta Life Science |
1 |
0 |
1 |
Claudin 18.2 expression 1 |
| Shenzhen Ionova Life Sciences |
1 |
0 |
1 |
KRAS G12D 1 |
| Shenzhen NewDEL Biotech |
1 |
0 |
2 |
RET fusion or mutation 1NTRK1/2/3 fusion 1 |
| Shijiazhuang Yiling Pharmaceutical |
1 |
1 |
1 |
FLT3 mutation (ITD/TKD) 1 |
| Sumitomo Pharma America |
1 |
0 |
2 |
FLT3 mutation (ITD/TKD) 1NPM1 mutation 1 |
| Summit Therapeutics |
1 |
1 |
1 |
EGFR exon 19 deletion / L858R 1 |
| SUNHO Biopharmaceutical |
1 |
1 |
1 |
HER2-low / ultralow (IHC 1+ or 2+/ISH-) 1 |
| Suzhou Abogen Biosciences |
1 |
0 |
0 |
|
| Suzhou Biomissile Pharmaceuticals |
1 |
0 |
1 |
MSI-H / dMMR 1 |
| Suzhou Immunofoco Biotechnology |
1 |
1 |
1 |
Claudin 18.2 expression 1 |
| Suzhou Junjing BioSciences |
1 |
0 |
1 |
EGFR exon 19 deletion / L858R 1 |
| Suzhou Puhe Pharmaceutical Technology |
1 |
1 |
3 |
EGFR exon 19 deletion / L858R 1EGFR exon 20 insertion 1HER2 (ERBB2) activating mutation 1 |
| SynDevRx |
1 |
0 |
1 |
PIK3CA activating mutation 1 |
| Taizhou Hanzhong biomedical |
1 |
1 |
1 |
MSI-H / dMMR 1 |
| Tavotek Biotherapeutics |
1 |
0 |
1 |
HER2-low / ultralow (IHC 1+ or 2+/ISH-) 1 |
| Totus Medicines |
1 |
0 |
1 |
PIK3CA activating mutation 1 |
| TRIANA Biomedicines |
1 |
0 |
1 |
ALK fusion 1 |
| Triumvira Immunologics |
1 |
0 |
1 |
Claudin 18.2 expression 1 |
| Twinpig Biolab |
1 |
0 |
1 |
MSI-H / dMMR 1 |
| Tyligand Pharmaceuticals |
1 |
0 |
1 |
KRAS G12D 1 |
| Vivace Therapeutics |
1 |
0 |
1 |
EGFR exon 19 deletion / L858R 1 |
| VM Oncology |
1 |
0 |
1 |
NTRK1/2/3 fusion 1 |
| Voronoi |
1 |
0 |
1 |
EGFR exon 19 deletion / L858R 1 |
| Vyriad |
1 |
0 |
0 |
|
| Xadcera Biopharmaceutical |
1 |
0 |
0 |
|
| Xencor |
1 |
0 |
1 |
MSI-H / dMMR 1 |
| Xynomic Pharmaceuticals |
1 |
0 |
0 |
|
| Yuhan |
1 |
0 |
2 |
EGFR exon 20 insertion 1HER2 (ERBB2) activating mutation 1 |